224 related articles for article (PubMed ID: 32852312)
1. Neurological complications of chimeric antigen receptor T cells and immune-checkpoint inhibitors: ongoing challenges in daily practice.
Berzero G; Picca A; Psimaras D
Curr Opin Oncol; 2020 Nov; 32(6):603-612. PubMed ID: 32852312
[TBL] [Abstract][Full Text] [Related]
2. Neurological Immunotoxicity from Cancer Treatment.
Wesley SF; Haggiagi A; Thakur KT; De Jager PL
Int J Mol Sci; 2021 Jun; 22(13):. PubMed ID: 34201529
[TBL] [Abstract][Full Text] [Related]
3. Immune-Driven Pathogenesis of Neurotoxicity after Exposure of Cancer Patients to Immune Checkpoint Inhibitors.
VilariƱo N; Bruna J; Kalofonou F; Anastopoulou GG; Argyriou AA
Int J Mol Sci; 2020 Aug; 21(16):. PubMed ID: 32796758
[TBL] [Abstract][Full Text] [Related]
4. Central nervous system injury from novel cancer immunotherapies.
Winter SF; Vaios EJ; Dietrich J
Curr Opin Neurol; 2020 Dec; 33(6):723-735. PubMed ID: 32941192
[TBL] [Abstract][Full Text] [Related]
5. Neurological Complications of CAR T Cell Therapy.
Landry K; Thomas AA
Curr Oncol Rep; 2020 Jul; 22(8):83. PubMed ID: 32607727
[TBL] [Abstract][Full Text] [Related]
6. Advances in treatments of patients with classical and emergent neurological toxicities of anticancer agents.
Bompaire F; Birzu C; Bihan K; Desestret V; Fargeot G; Farina A; Joubert B; Leclercq D; Nichelli L; Picca A; Tafani C; Weiss N; Psimaras D; Ricard D
Rev Neurol (Paris); 2023 Jun; 179(5):405-416. PubMed ID: 37059646
[TBL] [Abstract][Full Text] [Related]
7. CAR-T and checkpoint inhibitors: toxicities and antidotes in the emergency department.
Lipe DN; Shafer S
Clin Toxicol (Phila); 2021 May; 59(5):376-385. PubMed ID: 33576256
[TBL] [Abstract][Full Text] [Related]
8. Association between immune-related side effects and efficacy and benefit of immune checkpoint inhibitors - A systematic review and meta-analysis.
Hussaini S; Chehade R; Boldt RG; Raphael J; Blanchette P; Maleki Vareki S; Fernandes R
Cancer Treat Rev; 2021 Jan; 92():102134. PubMed ID: 33302134
[TBL] [Abstract][Full Text] [Related]
9. Advances in immune checkpoint inhibitors induced-cardiotoxicity.
Li X; Peng W; Wu J; Yeung SJ; Yang R
Front Immunol; 2023; 14():1130438. PubMed ID: 36911712
[TBL] [Abstract][Full Text] [Related]
10. CAR-T Cell Therapy in Cancer: Tribulations and Road Ahead.
Zhang Q; Ping J; Huang Z; Zhang X; Zhou J; Wang G; Liu S; Ma J
J Immunol Res; 2020; 2020():1924379. PubMed ID: 32411789
[TBL] [Abstract][Full Text] [Related]
11. Immune-related Adverse Events Associated with Cancer Immunotherapy: A Review for the Practicing Rheumatologist.
Jamal S; Hudson M; Fifi-Mah A; Ye C
J Rheumatol; 2020 Feb; 47(2):166-175. PubMed ID: 31308203
[TBL] [Abstract][Full Text] [Related]
12. Cardiotoxicity associated with immune checkpoint inhibitors and CAR T-cell therapy.
Lipe DN; Rajha E; Wechsler AH; Gaeta S; Palaskas NL; Alhajji Z; Viets-Upchurch J; Chaftari P
Am J Emerg Med; 2021 Dec; 50():51-58. PubMed ID: 34274878
[TBL] [Abstract][Full Text] [Related]
13. Neurotoxicity associated with cancer immunotherapy: immune checkpoint inhibitors and chimeric antigen receptor T-cell therapy.
Perrinjaquet C; Desbaillets N; Hottinger AF
Curr Opin Neurol; 2019 Jun; 32(3):500-510. PubMed ID: 30893101
[TBL] [Abstract][Full Text] [Related]
14. Immune checkpoint inhibitors and vasculitis.
Boland P; Heath J; Sandigursky S
Curr Opin Rheumatol; 2020 Jan; 32(1):53-56. PubMed ID: 31599800
[TBL] [Abstract][Full Text] [Related]
15. A Concise Review of Neurologic Complications Associated with Chimeric Antigen Receptor T-cell Immunotherapy.
Ruff MW; Siegler EL; Kenderian SS
Neurol Clin; 2020 Nov; 38(4):953-963. PubMed ID: 33040871
[TBL] [Abstract][Full Text] [Related]
16. Immune checkpoint inhibitors: maximizing benefit whilst minimizing toxicity.
Fahey CC; Gracie TJ; Johnson DB
Expert Rev Anticancer Ther; 2023 Jul; 23(7):673-683. PubMed ID: 37194222
[TBL] [Abstract][Full Text] [Related]
17. What the Cardiologist Needs to Know About Cancer Immunotherapies and Complications.
Frayberg M; Yung A; Zubiri L; Zlotoff DA; Reynolds KL
Curr Treat Options Oncol; 2021 May; 22(6):53. PubMed ID: 34037918
[TBL] [Abstract][Full Text] [Related]
18. T-cell-based Immunotherapies for Haematological Cancers, Part A: A SWOT Analysis of Immune Checkpoint Inhibitors (ICIs) and Bispecific T-Cell Engagers (BiTEs).
Rallis KS; Hillyar CRT; Sideris M; Davies JK
Anticancer Res; 2021 Mar; 41(3):1123-1141. PubMed ID: 33788704
[TBL] [Abstract][Full Text] [Related]
19. Severe Neurological Toxicity of Immune Checkpoint Inhibitors: Growing Spectrum.
Dubey D; David WS; Reynolds KL; Chute DF; Clement NF; Cohen JV; Lawrence DP; Mooradian MJ; Sullivan RJ; Guidon AC
Ann Neurol; 2020 May; 87(5):659-669. PubMed ID: 32086972
[TBL] [Abstract][Full Text] [Related]
20. Neurotoxicity of Cancer Immunotherapies Including CAR T Cell Therapy.
Song KW; Scott BJ; Lee EQ
Curr Neurol Neurosci Rep; 2023 Dec; 23(12):827-839. PubMed ID: 37938472
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]